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Pancytopenia, hepatosplenomegaly and skeletal complications are hallmarks of Gaucher disease. Monitoring of the outcome of therapy on
skeletal status of Gaucher patients is problematic since currently available imaging techniques are expensive and not widely accessible. The
availability of a blood test that relates to skeletal manifestations would be very valuable. We here report that macrophage inflammatory protein
(MIP)-1α and MIP-1β, both implicated in skeletal complications in multiple myeloma (MM), are significantly elevated in plasma of Gaucher
patients. Plasma MIP-1α of patients (median 78 pg/ml, range 21–550 pg/ml, n = 48) is elevated (normal median 9 pg/ml, range 0–208 pg/ml,
n = 39). Plasma MIP-1β of patients (median 201 pg/ml, range 59–647 pg/ml, n = 49) is even more pronouncedly increased (normal median 17 pg/
ml, range 1–41 pg/ml, n = 39; one outlier: 122 pg/ml). The increase in plasma MIP-1β levels of Gaucher patients is associated with skeletal
disease. The plasma levels of both chemokines decrease upon effective therapy. Lack of reduction of plasma MIP-1β below 85 pg/ml during
5 years of therapy was observed in patients with ongoing skeletal disease. In conclusion, MIP-1α and MIP-1β are elevated in plasma of Gaucher
patients and remaining high levels of MIP-1β during therapy seem associated with ongoing skeletal disease.
© 2007 Elsevier B.V. All rights reserved.Keywords: Gaucher disease; MIP-1α; MIP-1β; Bone; Skeletal disease1. Introduction
Type 1 Gaucher disease is the most frequently encountered
lysosomal storage disorder. Deficiency in glucocerebrosidase
(EC 3.2.1.45) results in massive storage of the glycosphingo-
lipid glucosylceramide in lysosomes of tissue macrophages [1].
The characteristic lipid-laden macrophages, so-called Gaucher
cells, secrete various factors involved in local tissue damage and
further formation of storage cells [2]. Accumulation of these
cells in liver, spleen, and bone marrow leads to pronounced
hepatosplenomegaly, pancytopenia and bone manifestations,
such as avascular necrosis, pathological fractures, bone pain and
bone crises. In addition, radiological evidence of Gaucher
related skeletal pathology, such as decreased signal intensity on⁎ Corresponding author. Tel.: +31 20 5665156; fax: +31 20 6915519.
E-mail address: j.m.aerts@amc.uva.nl (J.M. Aerts).
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doi:10.1016/j.bbadis.2007.04.002MRI, reflecting bone marrow infiltration, lytic lesions and
osteopenia, is often present [1]. Several plasma abnormalities
have been noted in Gaucher patients (see Aerts et al. [2]). The
most striking plasma marker reflecting the presence of Gaucher
cells was discovered a decade ago [3]. The activity of
chitotriosidase (EC 3.2.1.14), a human analogue of chitinases
from lower animals, was found to be on average 1000-fold
elevated in plasma of symptomatic Gaucher patients. Monitor-
ing of plasma chitotriosidase is now used for decision making
regarding initiation and optimization of therapeutic interven-
tions. More recently, a second Gaucher cell marker was
identified. CCL18, a member of the human C–C chemokine
family, is elevated 10- to 50-fold in plasma of Gaucher patients
without overlap between patient and control values [4]. CCL18,
also known as PARC (pulmonary and activation-regulated
chemokine), was already known to be up-regulated in Gaucher
spleen [5]. Chitotriosidase and CCL18 both stem from Gaucher
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and ACE [2], is a useful alternative to monitor Gaucher patients
[4,6–8], especially when dealing with chitotriosidase deficient
individuals [9]. The plasma markers chitotriosidase and CCL18
reflect the total body burden of storage cells, but do not correlate
with specific clinical symptoms. In particular, the degree of
skeletal involvement does not correlate with total Gaucher cell
burden. Currently, there are no plasma or urinary biomarkers
predicting onset or progression of bone involvement in Gaucher
disease. Several studies have indicated that classical osteopo-
rosis markers reflecting osteoclast activity do not correlate well
with skeletal disease in Gaucher patients [10,11]. The lumbar
spine bone mineral density as assessed by DXA has been found
to be on average lower in Gaucher patients as compared with a
reference population and to improve upon therapy [12,13].
Two costly therapies are registered for the treatment of type 1
Gaucher disease. First developed was enzyme replacement
therapy (ERT), a treatment based on chronic intravenous
administration of human placental glucocerebrosidase [14],
nowadays recombinant enzyme [15]. ERT results in spectacular
improvement of the visceral and hematological problems in
Gaucher patients. Another registered therapeutic intervention
for type 1 Gaucher disease is substrate reduction therapy (SRT),
based on oral administration of N-butyldeoxynojirimycin
(Zavesca), an inhibitor of glucosylceramide biosynthesis [16].
SRT results in clinical improvements in mildly to moderately
affected type 1 Gaucher patients [17]. The efficacy of both ERT
and SRT regarding skeletal disease has been, and still remains,
topic of debate (see for example Weinreb et al. [18]). Successful
treatment is predicated on monitoring response and making
appropriate adjustments based on achievement of defined
therapeutic goals [19]. However, monitoring the effect of
treatment on skeletal manifestations of Gaucher disease is
problematical. One advocated approach is to monitor bone
mineral density, which may relate to the risk for fractures [11].
In severe skeletal disease its use is however limited to the
diffusely involved skeletal parts and a relation with Gaucher
related bone complications has so far not been established. A
favored approach is the measurement of lumbar bone marrow
fat fraction by quantitative chemical shift imaging [20]. A low
fat fraction, reflecting massive Gaucher cell infiltration, is
associated with a high risk for skeletal complications [20,21]. A
limitation of this technique is that it is expensive, time
consuming and not widely available.
Given the present limitations, we started a search for a
plasma parameter that may relate to skeletal disease in Gaucher
patients. For this purpose, we focused on chemokines critical to
bone homeostasis. Earlier microarray experiments performed in
our laboratory indicated that the mRNAs encoding chemokines
macrophage inflammatory protein (MIP)-1α and MIP-1β were
up-regulated in the spleen of a symptomatic Gaucher patient 8-
fold and 17-fold, respectively, when compared to control
spleens. The two chemokines are of special interest since they
have recently been implicated in the pathogenesis of skeletal
disease in patients suffering from multiple myeloma (MM)
[22,23]. In this study we report on the plasma levels of the
chemokines MIP-1α and MIP-1β in type 1 Gaucher patients,their relationship with bone complications and their association
with ongoing skeletal disease during therapeutic intervention.
2. Patients, materials, and methods
2.1. Gaucher disease patients and controls
Control subjects consisted of 18 male (mean age 39 years, range 24–54) and
21 female healthy volunteers (mean age 38 years, range 23–54). All patients
with Gaucher disease type 1 studied (25 males (mean age 39 years, range 16–67)
and 24 females (mean age 39 years, range 12–66)) were known by referral to the
Academic Medical Center. Of the 49 type I patients, 46 received ERT
(alglucerase, imiglucerase, Genzyme, Cambridge, MA, individualized dosing
[24]) while 3 patients were not treated. EDTA (ethylenediaminetetraacetic acid)
plasma and serum samples were obtained before and during therapeutic
intervention. To assess the clinical severity of patients the Severity Score Index
(SSI) was used [25,26]. Skeletal disease was defined as having a history of at
least one of the following severe bone complications, prior to start of ERT; bone
crises, avascular necrosis or pathological fractures. Ongoing skeletal disease
after start of therapy was defined as developing a new episode of one of the
above mentioned severe skeletal complications and/or experiencing periods of
aggravating bone pain, necessitating the use of pain medication, which was in
the opinion of the physician related to Gaucher disease. Bone marrow
involvement was assessed by measurement of the bone marrow fat fraction
using Dixon quantitative shift imaging (QCSI) of the lumbar spine [20,21]. Only
a single patient with ongoing skeletal disease received during the entire period of
analysis co-medication with bisphosphonates. Two patients, without skeletal
medications at start of therapy, received co-medication that may affect bone
metabolism during the last 2 and 4 years of analysis, respectively. Approval was
obtained from the Ethical Committee. Informed consent was provided according
to the Declaration of Helsinki.
2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
Levels of MIP-1α (in EDTA plasma), MIP-1β (in EDTA plasma and spleen
extracts) and osteoprotegerin (OPG) (in serum) were measured by sandwich
ELISA using commercially available DuoSet ELISA Developmental kits (R&D
Systems Inc. Minneapolis, MI), consisting of a capture antibody, a biotinylated
detection antibody, recombinant standard, and streptavidin-horseradish perox-
idase (HRP) conjugate. Assay conditions were exactly as described by the
manufacturer. No diurnal variation or impact of physical activity on MIP-1α or
MIP-1β levels was observed in five normal subjects.
Levels of soluble receptor activator of NFκB (sRANKL) in EDTA plasma
and serum were measured by ELISA using a commercially available enzyme
immunoassay (Biomedica Medizinprodukte GmbH &b Co, Wien, Austria),
consisting of a microtiter plate pre-coated with recombinant OPG, a biotinylated
anti-sRANKL antibody, recombinant standard, control sample and ready to use
streptavidin-HRP conjugate and TMB substrate. Although assay conditions
were exactly as described by the manufacturer we could not reliably detect
sRANKL in Gaucher plasma or serum samples. The manufacturer warns for
complications when lipidemic or hemolyzed samples are used. Even analysis of
freshly obtained blood samples from Gaucher patients gave poor results,
suggesting that analysis was intrinsically hampered by the known lipidemic and/
or hemolytic nature of Gaucher patient materials.
Levels of CCL18 in EDTA plasma were measured by a sandwich ELISA
using a commercially available CytoSet (Biosource International, Camarillo,
CA), consisting of a capture antibody, a biotinylated detection antibody,
recombinant CCL18/PARC standard, and streptavidin-HRP conjugate. Assay
conditions were exactly as described by the manufacturer.
2.3. Enzyme activity assays
The standard enzyme activity assay for chitotriosidase with 4 MU-
chitotriose (4-methylumbelliferyl β-D-N,N′,N′′-triacetylchitotriose; Sigma
Chemical Company, St. Louis, MI) as substrate was performed at pH 5.2, as
previously described [3]. Chitotriosidase values of patients who were
heterozygous for the chitotriosidase mutation were multiplied by 2 [3,27].
Fig. 1. Plasma levels of MIP-1α and MIP-1β in controls and Gaucher patients.
(A) Plasma MIP-1α levels in control subjects (n = 39) and Gaucher patients
(n = 48). (B) Plasma MIP-1β levels in control subjects (n = 39) and Gaucher
patients (n = 49). Chemokine concentrations were determined as described in
Patients, materials, and methods. The horizontal line represents the median value
in each group. P-values (two-tailed Mann–Whitney rank sum test) are indicated
when subgroups were statistically different.
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Immunohistochemistry was performed on frozen sections of Gaucher spleen to
detect MIP-1β expression patterns. The methodology of immunocytochemical
procedures has been described in detail previously [28]. Frozen sections of 6 μm
were cut and thaw-mounted on glass slides. Slides were kept overnight at room
temperature (RT) in humidified atmosphere. After air-drying the slides for 1 h, they
were fixed in fresh acetone containing 0.02% (vol/vol) hydrogen peroxide. Slides
were then air-dried for 10 min, washed with phosphate-buffered saline, and
incubated with optimally diluted anti-MIP-1β antibody (mouse anti-human MIP-
1β; R&D Systems Inc.) overnight at 4 °C in a humidified atmosphere. Incubations
with secondary rabbit antimouse–Ig–biotin (Dako, Glostrup, Denmark) and
tertiary HRP-labeled avidin–biotin-complex (ABC/HRP; Dako) were performed
for 1 h at RT. Between incubation steps slides were washed twice with phosphate-
buffered saline. HRP activity was revealed by incubation for 10 min at RTwith 3-
amino-9-ethyl-carbazole (AEC; SigmaChemical Company), leading to a bright red
precipitate. After washing, sections were counterstained with hematoxylin and
embedded with glycerol-gelatin. Primary antibody reagent omission control
staining was performed. Photomicrographs were acquired using a Zeiss axioskop
microscope equipped with 10 × /0.30 numeric aperture, and 40 × /0.75 numeric
aperture Zeiss PlanNeofluar objectives and a Zeiss AxioCamMRc5 digital camera
operating with AxioVision AC release 4.5 as acquisition software.
2.5. Preparation of spleen extracts
Spleen extracts were prepared from frozen spleens of 2 control individuals
and 4 Gaucher patients. Ten gram of frozen spleen, which had been stored at
−80 °C, was minced into little pieces and 30 ml distilled water was added. This
suspension was thoroughly homogenized and sonicated 5 times 15 s on/off at 6
μm, MSE. All procedures were performed on ice. Subsequently the extract was
centrifuged for 30 min at 12000 rpm (rotor SS34, Sorvall RC-5b Du Pont
Instruments, Wilmington, DE) at 4 °C. The supernatant was removed and stored
at −20 °C as an aqueous spleen extract.
2.6. Statistical analysis
Results are given as median and range. Mann–Whitney U test analysis was
used for the following comparisons: Biomarker levels of control subjects and
Gaucher patients, Gaucher patients with or without skeletal disease and Gaucher
patients with or without splenectomy. To make biomarker level comparisons
between patients before and after therapy, data were analyzed using the paired t test.
Correlations were tested by the rank correlation test (Spearman coefficient, ρ).
Differences in the percentage of patients with QCSI and MIP-1β levels above
defined thresholds were assessed by Chi-square test. Sensitivity and specificity
were determined using two by two table analysis. Results were considered to be
statistically significant when two-tailed P-values were b 0.05.
3. Results
3.1. Plasma and splenic levels of MIP-1α and MIP-1β in
controls and Gaucher patients
MIP-1α levels were determined in plasma from 39 control
subjects and 48 symptomatic Gaucher patients prior to therapy
or not receiving therapy (Fig. 1A). The median plasma MIP-1α
level in Gaucher patients (78 pg/ml, range 21–550 pg/ml)
differed significantly (P b 0.0001) from that in control subjects
(9 pg/ml, range 0–208 pg/ml). Overlap was seen between values
in patients and control subjects. MIP-1β levels were measured in
plasma from 39 control subjects and 49 symptomatic Gaucher
patients prior to therapy or not receiving therapy (Fig. 1B). The
median plasma level in Gaucher patients (201 pg/ml, range 59–
647 pg/ml) differed significantly (P b 0.0001) from that in
control subjects (17 pg/ml, range 1–122 pg/ml). Apart from oneclear outlier in the control group, showing repeatedly a plasma
MIP-1β of 122 ± 5 pg/ml, there was no overlap.
MIP-1β levels in extracts from spleens of 2 control subjects
and 4 symptomatic Gaucher patients were determined. MIP-1β
levels were on average 2.5-fold elevated in Gaucher spleens.
The MIP-1β levels in the two control spleens and the four
Gaucher spleens were 1136, 1712, and 2376, 3136, 3912 and
4544 pg/gram spleen tissue, respectively.
3.2. Plasma levels of MIP-1α, MIP-1β and established Gaucher
cell markers
The relationship between plasma levels of the chemokines and
twowell-known biomarkers for Gaucher cells, chitotriosidase and
CCL18was established. PlasmaMIP-1α levels correlated weakly
with plasma chitotriosidase and very weakly with plasma CCL18
levels (Fig. 2A, B). The correlation of Gaucher cell markers with
plasma MIP-1β levels was even poorer (Fig. 2C, D).
3.3. Origin of MIP-1β
We performed immunohistochemistry to establish whether the
Gaucher cells and/or the surrounding cells are responsible for the
production of MIP-1β. Immunohistochemistry on frozen spleen
sections of 2 Gaucher patients revealed that mature Gaucher cells
hardly produce MIP-1β. Instead, some cells surrounding the
mature storage cells do produce MIP-1β (Fig. 3). This sharply
contrasts with the earlier histochemical finding that chitotriosidase
and CCL18 are produced by mature storage cells [4]. Thus, MIP-
Fig. 2. Relation of plasma levels of MIP-1α and MIP-1β with two established Gaucher cell markers chitotriosidase and CCL18. (A) Plasma MIP-1α versus plasma
chitotriosidase. (B) PlasmaMIP-1α versus plasma CCL18. (C) PlasmaMIP-1β versus plasma chitotriosidase. (D) PlasmaMIP-1β versus plasma CCL18. Correlations
were tested by the rank correlation test (Spearman coefficient, ρ). Gaucher patients without skeletal disease, amelioration of skeletal disease upon therapy and ongoing
skeletal disease during therapy are represented by a circle, a square and a triangle, respectively. Closed symbols represent chitotriosidase wild-type individuals; open
symbols, chitotriosidase carrier individuals for which chitotriosidase activity is corrected by doubling the measured activity.
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the direct environment of the Gaucher cells.
3.4. Effect of treatment on plasma levels of MIP-1α, MIP-1β,
chitotriosidase and CCL18
The effect of 3 (± 1) years ERT on plasma levels of MIP-1α
and MIP-1β was determined, and compared to changes in theFig. 3. Detection of MIP-1β protein by immunohistochemistry in Gaucher spleen.
frozen sections of Gaucher spleen (A, B) and human tonsil as an internal positive con
×100. (B) Magnification of the same (Gaucher spleen) section. Original magnification
swollen cells) do not have detectable levels of MIP-1β protein. Some surrounding
confirms MIP-1β protein expression as predicted. Original magnification ×100.Gaucher cell markers, chitotriosidase and CCL18. The median
plasma MIP-1α level in Gaucher patients was 79 pg/ml before
therapy (range 23–128 pg/ml, n = 16) and 23 pg/ml after therapy
(range 0–125 pg/ml, n = 16) (P b 0.0001). The median plasma
MIP-1β level in Gaucher patients was 199 pg/ml before therapy
(range 77–330 pg/ml, n = 16) and 40 pg/ml after therapy (range
9–182 pg/ml, n = 16) (P b 0.0001). The median chitotriosidase
activity in plasma of Gaucher patients was 14815 nmol/mlImmunohistochemistry, using an antibody against MIP-1β, was performed on
trol tissue (C). (A) Overview of Gaucher spleen section. Original magnification
×400. Stained Gaucher spleen sections show that Gaucher cells (clustered large
cells do show labeling. (C) Overview section of human tonsil (control tissue)
Fig. 4. Plasma levels ofMIP-1α andMIP-1β in Gaucher patients with or without
skeletal disease. (A) Plasma MIP-1α levels in Gaucher patients with (n = 20) or
without skeletal disease (n = 28). (B) Plasma MIP-1β levels in Gaucher patients
with (n = 21) or without skeletal disease (n = 28). Chemokine concentrations
were determined as described in Patients, materials, and methods. The horizontal
line represents the median value in each group. P-values (two-tailed Mann–
Whitney rank sum test) are indicated when subgroups were statistically different.
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5589 nmol/ml h after therapy (range 428–65244 nmol/ml h,
n = 15) (P = 0.0044). The median plasma CCL18 level in
Gaucher patients was 971 ng/ml before therapy (range 576–
1713 ng/ml, n = 10) and 361 ng/ml after therapy (range 112–
1584 ng/ml, n = 10) (P = 0.0007). Thus, ERT results in reductions
in plasma MIP-1α and MIP-1β levels in Gaucher patients.
3.5. Relation of plasma levels of MIP-1α and MIP-1β with
clinical symptoms
Plasma levels of MIP-1α or MIP-1β did not correlate with
severity of disease as judged by SSI, extent of splenomegaly or
hepatomegaly, or hematological abnormalities (as could be
deduced from the combination of Spearman coefficient ρ and
scatter in the plots of all cases). Plasma MIP-1α levels were not
significantly different in plasma of splenectomized Gaucher
patients (median 82 pg/ml, range 30–231 pg/ml, n = 16) as
compared those with a spleen (median 78 pg/ml, range 21–
550 pg/ml, n = 32). Plasma MIP-1β levels tended to be higher in
splenectomized Gaucher patients (median 234 pg/ml, range 115–
647 pg/ml, n = 17) compared to non-splenectomized Gaucher
patients (median 173 pg/ml, range 59–427 pg/ml, n = 32).
We examined whether increased plasma MIP-1α and MIP-
1β may be associated with skeletal disease in Gaucher patients.
For this purpose skeletal disease was strictly defined on the
basis of objective criteria such as a history of bone crises,
avascular necrosis or pathological fractures. Not included as
criteria were subjective bone pains or minor abnormalities in
bone mineral density. Fig. 4A shows the plasma MIP-1α levels
in untreated Gaucher patients without skeletal disease (median
59 pg/ml, range 21–550 pg/ml, n = 28) and untreated Gaucher
patients with skeletal disease (median 87 pg/ml, range 42–
344 pg/ml, n = 20). Plasma MIP-1α levels tended to be higher
in patients with skeletal disease compared to patients without
skeletal disease (P = 0.0121). Fig. 4B shows the plasma MIP-
1β levels in untreated Gaucher patients without skeletal disease
(median 154 pg/ml, range 59–427 pg/ml, n = 28) and those
with skeletal disease (median 252 pg/ml, range 77–647 pg/ml,
n = 21). Plasma MIP-1β levels also tended to be higher in
patients with skeletal disease compared to those without skeletal
disease (P = 0.0017). The increased plasma MIP-1β had a
stronger association with the presence of skeletal disease than
increased plasma MIP-1α.
3.6. Plasma MIP-1β levels and chitotriosidase in Gaucher
patients with or without amelioration of skeletal disease upon
therapy
MIP-1β levels were measured in plasma samples taken
before and after several years of therapeutic intervention. In
patients without skeletal disease plasma MIP-1β decreased in
all cases to levels b70 pg/ml. None of these patients developed
skeletal complications during therapy. Two additional catego-
ries of Gaucher patients were studied: those with skeletal
disease before therapy showing marked improvements during
therapy (n = 9) and those with ongoing skeletal disease duringtherapy (n = 9). Of the 9 patients with ongoing skeletal disease,
5 experienced a severe complication (two bone crisis, two
pathological fractures and one avascular necrosis) and 4
suffered from severe pain, as defined in Patients, materials,
and methods. Median dose and dosing frequency in patients
with ongoing skeletal disease (dose 30 U/kg/4 weeks, range 25–
40; frequency 4×/4 weeks, range 2–8) were not significantly
different from those in patients without such complications
(median 30 U/kg/4 weeks, range 15–120; frequency 4×/
4 weeks, range 2–8). Prior to therapy the median plasma MIP-
1β levels in the two categories of Gaucher patients were similar.
After 1 year of therapy plasma MIP-1β levels were significantly
higher in patients with ongoing skeletal disease as compared to
those without active skeletal disease (P = 0.0019) (Fig. 5A).
When analyzed after 1 year of treatment 5 of 9 Gaucher patients
without further bone complications during therapy already
showed a plasma MIP-1βb85 pg/ml whereas all Gaucher
patients with ongoing skeletal disease showed a plasma MIP-
1βN85 pg/ml. After 5 years of therapy plasma MIP-1β levels
differentiated even better between patients with a reduction of
skeletal disease upon therapy and patients with ongoing skeletal
disease (P = 0.0002) (see also Fig. 6B). When analyzed after
5 years of treatment, all Gaucher patients without further bone
complications during therapy showed a plasmaMIP-1βb85 pg/
Fig. 5. Effect of treatment (0, 1 and 5 years ERT) on MIP-1β levels and chitotriosidase in plasma of Gaucher patients with or without amelioration of skeletal disease
upon therapy. (A) PlasmaMIP-1β levels. (B) Plasma chitotriosidase levels. Gaucher patients with ongoing skeletal disease during therapy (n = 9) and Gaucher patients
with amelioration of skeletal disease upon therapy (n = 9) are represented by a red triangle and a blue circle, respectively. Closed symbols represent chitotriosidase
wild-type individuals; open symbols, chitotriosidase carrier individuals for which chitotriosidase activity is corrected by doubling the measured activity.
793M.J. van Breemen et al. / Biochimica et Biophysica Acta 1772 (2007) 788–796ml whereas 8 of 9 Gaucher patients with ongoing skeletal
disease still showed a plasma MIP-1βN85 pg/ml. A lack in
reduction of plasma MIP-1β below a critical threshold during
therapy (MIP-1βN85 pg/ml) seems associated with ongoing
skeletal disease.
We investigated whether plasma chitotriosidase could also
differentiate between Gaucher patients with and without
ongoing skeletal disease during enzyme therapy. Fig. 5B
shows that plasma chitotriosidase does not discriminate the
two categories of patients as powerful as plasma MIP-1β. After
1 year (P = 0.0047) and 5 years of therapy (P = 0.0205),
chitotriosidase activity also tended to be higher in patients with
ongoing skeletal disease as compared with improving patients.
However there was far more overlap between the two categories
as noted for plasma MIP-1β levels.
3.7. Effect of treatment on the fat fraction of the lumbar spine
and plasma MIP-1β levels
Earlier analysis of a large cohort of Gaucher patients has
revealed that bone complications occurred primarily in patients
with a lumbar marrow fat fraction of less than 23% [20].
Univariate logistic regression analysis indicated that for every
decrease of 10% of the fat fraction, the risk of bonecomplications increased with 85%. Individuals with a fat
fraction below 23%, before treatment, are thus considered to be
at high risk for bone complications, defined as avascular
necrosis, bone crises or pathological fractures [20]. Normal
values of fat fraction in healthy volunteers have been
determined at 37%±8 [29]. During therapy, an increase of fat
fraction occurs [21], but remains below 1SD of the normal value
(29%) in a subset of patients. All patients in this study, who
experienced ongoing skeletal disease defined as stated above,
had a fat fraction that remained below 29%, except for one
patient, who reached a fat fraction of 51%. This individual
showed persistently elevated plasma MIP-1β, being still
152 pg/ml after 5 years of therapy.
Fig. 6A shows the typical changes during therapy in
lumbar fat fractions (L3–5) in a Gaucher patient with ongoing
skeletal disease (upper panel) and an individual with a good
skeletal response to therapy (lower panel). When we compare
Gaucher patients with and without ongoing skeletal disease
after a mean period of 5 years of therapy with respect to their
values of bone marrow fat fractions and plasma MIP-1β, it
becomes clear that most patients with ongoing skeletal disease
have a high plasma MIP-1β (N85 pg/ml) and a low fat fraction
(Fig. 6B). Gaucher patients without further bone complica-
tions during therapy all show relatively lowMIP-1β (b85 pg/ml)
Fig. 6. Effect of treatment on the fat fraction of the lumbar spine and plasma MIP-1β levels. (A) Examples of response in bone marrow fat fraction of the lumbar spine
upon therapy as visualized by QCSI. Upper panel: characteristic response in patients showing ongoing skeletal disease. Lower panel: characteristic response in patients
without bone complications during therapy. (B) Plasma MIP-1β levels and lumbar bone marrow fat fraction after 5 years of therapy. Plasma MIP-1β levels (circles)
and lumbar bone marrow fat fractions (triangles) in patients with ongoing skeletal disease (left panel) and those without (right panel).
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1β can be of additional value for the assessment of ongoing
skeletal disease. For example, when thresholds of 29% for
bone marrow fat fraction are combined with MIP-1β levels
above 85 pg/ml, the specificity of the combined measurement
is greatly enhanced.4. Discussion
Our investigation revealed that plasma levels of the chemo-
kines MIP-1α and MIP-1β are markedly increased in Gaucher
patients. Particularly plasma MIP-1β levels tend to be higher in
untreated patients with skeletal disease compared to untreated
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balance between bone resorption and formation is clearly
disturbed, favoring bone loss. In postmenopausal osteoporosis,
bone loss can be attributed to more generalized ‘uncoupled’ bone
remodeling with enhanced osteolytic resorption by osteoclasts
and decreased bone formation by osteoblasts. For Gaucher
patients, seemingly conflicting results have been reported on
markers of bone formation and resorption [11]. At least, no clear-
cut indications for classical osteoporosis have been firmly
documented. This suggests that special mechanisms contribute
to the skeletal disease in Gaucher patients. It is conceivable that,
among other factors, chemokines like MIP-1β play an important
role in the disturbed balance of bone resorption and formation in
Gaucher patients. Abe et al. [22] showed that MIP-1α and MIP-
1β enhance osteoclastic bone resorption in multiple myeloma
(MM). They induce local expression ofRANKL that after binding
to its receptor RANK stimulates osteoclast differentiation and
activity. OPG is a decoy receptor for RANKL, inhibiting its
biological activity [30]. The local RANKL/OPG ratio is therefore
thought to determine the level of osteoclast mediated bone
resorption [30–32]. Information on the RANKL/OPG ratio in
marrow of Gaucher patients is still lacking. We were unable to
detect abnormalities in OPG in Gaucher serum samples. A
comparable finding was very recently reported by Magal et al.
[33]. sRANKL could not be reliably detected in Gaucher serum
samples (see Patients, materials, and methods). It will be of
interest to study more closely the presence of MIP-1α and MIP-
1β in Gaucher bone marrow as well as the RANK/RANKL/OPG
system. It should be noted that the increases in circulatingMIP-1α
andMIP-1β of Gaucher patients are very pronounced. To the best
of our knowledge no data on MIP-1β in serum of MM patients
have been published. There are a couple of literature reports on
MIP-1α levels in serum of MM patients. In general, a modest
increase (about 3-fold) has been reported, although absolute
numbers may differ dependent on the analytical method used
(see for a review Terpos et al. [34]).
The present data regarding spleen indicate that MIP-1β stems
not directly from storage cells, but rather cells surrounding
Gaucher cells. An earlier investigation already indicated that
lipid-laden Gaucher cells in the spleen are alternatively activated
and surrounded by cells expressing macrophage markers [35].
Indeed, MIP-1α and MIP-1β have been proposed as markers of
pro-inflammatory macrophages, whilst chitotriosidase and
CCL18 are viewed as markers of alternatively activated cells
[36]. The observations with Gaucher spleen might not be
extrapolated to the bone marrow. It is possible that Gaucher
cells in the bone marrow microenvironment have somewhat
different characteristics than splenic Gaucher cells. Further
research is warranted to establish whether MIP proteins directly
underlie disease processes in the bone marrow. The recent
availability of suitable Gaucher mouse models should allow such
investigations [37]. The present study did not address the
relationship between levels of MIP-1α andMIP-1β and localized
osteolysis or generalized osteopenia/osteoporosis. Future inves-
tigations should address these potential relationships.
Interestingly, analysis of Gaucher patients with ongoing
skeletal disease during therapy and those without revealeddifferences in plasma MIP-1β. After 5 years of therapy plasma
MIP-1β levels remained relatively high (N70 pg/ml) in most
Gaucher patients showing ongoing skeletal disease. In contrast,
all patients showing no skeletal disease upon 5 years therapy
had relative low plasma MIP-1β levels (b85 pg/ml). It is of
interest to note that high plasma MIP-1β at the start of treatment
does not predict the skeletal response to treatment.
At present the most sensitive method to assess the risk for
skeletal disease is quantitative chemical shift imaging of lumbar
marrow. Fat fractions below 23% in the marrow of L3–5
constitute a high risk for skeletal complications [20]. However,
in some Gaucher patients without ongoing skeletal disease
during therapy fat fractions nevertheless remain low. All such
patients show after 5 years therapy reassuring low plasma MIP-
1β levels b85 pg/ml. The specificity of MIP-1β to predict
amelioration of bone disease is thus better than QCSI alone.
Although additional studies need to prove this, it is our
impression that the use of plasma MIP-1β to lumbar marrow fat
fraction further improves the assessment of risk for skeletal
disease during therapy.
In conclusion, elevated MIP-1α and MIP-1β levels are
newly documented plasma abnormalities in Gaucher patients. In
particular the increase in MIP-1β seems associated with skeletal
disease. Further research with larger groups of well-documented
Gaucher patients will have to reveal whether plasma MIP-1β
levels can be of additional value in clinical management of
Gaucher patients, particularly for the management and
prediction of their skeletal disease. Moreover, additional studies
are necessary to clarify whether MIP-1β plays a direct role in
the pathophysiology of skeletal problems in Gaucher patients
via the RANK/RANKL/OPG system.
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